Hydrogen sulfide protects from colitis and restores intestinal microbiota biofilm and mucus production

Inflammatory Bowel Diseases

Volumn 21, Issue 5, 2015, Pages 1006-1017

  Motta, Jean Paul ^a   Flannigan, Kyle L ^b   Agbor, Terence A ^b   Beatty, Jennifer K ^a   Blackler, Rory W ^b   Workentine, Matthew L ^b   Da Silva, Gabriela J ^c   Wang, Rui ^d   Buret, Andre G ^a   Wallace, John L ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d LAKEHEAD UNIVERSITY   (Canada)

Author keywords

biofilm; colitis; hydrogen sulfide; IBD; microbiota; mucus

Indexed keywords

DIALLYL DISULFIDE; DNA; HYDROGEN SULFIDE; MYELOPEROXIDASE; POLYSACCHARIDE; PROTEIN; RNA; DEXTRAN SULFATE; GASOTRANSMITTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL TRANSLOCATION; BIOSYNTHESIS; CELL INFILTRATION; CELL STRUCTURE; COLITIS; COLON FLORA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; ENZYME ACTIVITY; ESCHERICHIA COLI; EX VIVO STUDY; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; INTESTINE FLORA; MALE; MICROBIAL BIOMASS; MICROBIAL GROWTH; MICROBIAL VIABILITY; MOUSE; MUCUS SECRETION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RAT; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; SCORING SYSTEM; STAPHYLOCOCCUS AUREUS; THICKNESS; TISSUE INJURY; ULCER; WEIGHT REDUCTION; ANIMAL; BIOFILM; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; FLUORESCENCE IN SITU HYBRIDIZATION; INTESTINE MUCOSA; METABOLISM; MICROBIOLOGY; MUCUS; SECRETION (PROCESS); WISTAR RAT;

ANIMALS; BIOFILMS; COLITIS; DEXTRAN SULFATE; GASOTRANSMITTERS; GASTROINTESTINAL MICROBIOME; HUMANS; HYDROGEN SULFIDE; IN SITU HYBRIDIZATION, FLUORESCENCE; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; MUCUS; RATS; RATS, WISTAR;

EID: 84929037788     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000345     Document Type: Article

References (55)

1. Wang R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol Rev. 2012;92:791-896.
2. Wallace JL, Blackler RW, Chan MV, et al. Anti-inflammatory and cytoprotective actions of hydrogen sulfide: translation to therapeutics. Antioxid Redox Signal. 2015;22:398-410.
3. Wallace JL, Dicay M, McKnight W, et al. Hydrogen sulfide enhances ulcer healing in rats. FASEB J. 2007;21:4070-4076.
4. Wallace JL, Vong L, McKnight W, et al. Endogenous and exogenous hydrogen sulfide promotes resolution of colitis in rats. Gastroenterology. 2009;137:569-578.
5. Ankri S, Mirelman D. Antimicrobial properties of allicin from garlic. Microbes Infect. 1999;1:125-129.
6. Macpherson A, Khoo UY, Forgacs I, et al. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut. 1996; 38:365-375.
7. Rietdijk ST, D'Haens GR. Recent developments in the treatment of inflammatory bowel disease. J Dig Dis. 2013;14:282-287.
8. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146: 1489-1499.
9. Peterson DA, Frank DN, Pace NR, et al. Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe. 2008;3:417-427.
10. Andoh A, Imaeda H, Aomatsu T, et al. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol. 2011;46:479-486.
11. Macfarlane S, McBain AJ, Macfarlane GT. Consequences of biofilm and sessile growth in the large intestine. Adv Dent Res. 1997;11:59-68.
12. Swidsinski A, Weber J, Loening-Baucke V, et al. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol. 2005;43:3380-3389.
13. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318-1322.
14. Flemming HC, Wingender J. The biofilm matrix. Nat Rev Microbiol. 2010;8:623-633.
15. Buret AG, Reti K. Acute enteric infections alter commensal microbiota: new mechanisms in post-infectious intestinal inflammatory disorders. In: Heidt PJ, Lang D, Riddle MS, et al, eds. Old Herborn University Seminar Monograph: Persisting Consequences of Intestinal Infection. 2014;27:87-100.
16. Kalischuk LD, Inglis GD, Buret AG. Campylobacter jejuni induces transcellular translocation of commensal bacteria via lipid rafts. Gut Pathog. 2009;1:2.
17. Kalischuk LD, Buret AG. A role for Campylobacter jejuni-induced enteritis in inflammatory bowel disease?. Am J Physiol Gastrointest Liver Physiol. 2010;298:G1-G9.
18. O'Hara JR, Feener TD, Fischer CD, et al. Campylobacter jejuni disrupts protective toll-like receptor 9 signaling in colonic epithelial cells and increases the severity of dextran sulfate sodium-induced colitis in mice. Infect Immun. 2012;80:1563-1571.
19. Wallace JL, Keenan CM. An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am J Physiol Gastrointest Liver Physiol. 1990;258:G527-G534.
20. Boughton-Smith NK, Wallace JL, Whittle BJ. Relationship between arachidonic acid metabolism, myeloperoxidase activity and leukocyte infiltration in a rat model of inflammatory bowel disease. Agents Actions. 1988;25:115-123.
21. Ceri H, Olson ME, Stremick C, et al. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol. 1999;37:1771-1776.
22. Flannigan KL, Ferraz JG, Wang R, et al. Enhanced synthesis and diminished degradation of hydrogen sulfide in experimental colitis: a sitespecific, pro-resolution mechanism. PLoS One. 2013;8:e71962.
23. Hall-Stoodley L, Stoodley P. Biofilm formation and dispersal and the transmission of human pathogens. Trends Microbiol. 2005;13:7-10.
24. Plevy SE, Targan SR. Future therapeutic approaches for inflammatory bowel diseases. Gastroenterology. 2011;140:1838-1846.
25. D'Haens GR, Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology. 2008;135:1123-1129.
26. Sommer F, Backhed F. The gut microbiota-masters of host development and physiology. Nat Rev Microbiol. 2013;11:227-238.
27. Vlamakis H, Chai Y, Beauregard P, et al. Sticking together: building a biofilm the Bacillus subtilis way. Nat Rev Microbiol. 2013;11:157-168.
28. von Rosenvinge EC, O'May GA, Macfarlane S, et al. Microbial biofilms and gastrointestinal diseases. Pathog Dis. 2013;67:25-38.
29. Lu X, Rasco BA, Jabal JM, et al. Investigating antibacterial effects of garlic (Allium sativum) concentrate and garlic-derived organosulfur compounds on Campylobacter jejuni by using fourier transform infrared spectroscopy, Raman spectroscopy, and electron microscopy. Appl Environ Microbiol. 2011;77:5257-5269.
30. Feng S, Eucker TP, Holly MK, et al. Investigating the responses of Cronobacter sakazakii to garlic-drived organosulfur compounds: a systematic study of pathogenic-bacterium injury by use of high-Throughput wholetranscriptome sequencing and confocal micro-raman spectroscopy. Appl Environ Microbiol. 2014;80:959-971.
31. Ross ZM, O'Gara EA, Hill DJ, et al. Antimicrobial properties of garlic oil against human enteric bacteria: evaluation of methodologies and comparisons with garlic oil sulfides and garlic powder. Appl Environ Microbiol. 2001;67:475-480.
32. Buret AG, Akierman SV, Rioux KP, et al. Giardia duodenalis modulates human intestinal microbial biofilm composition and structure: a role in irritable bowel syndrome?. Gastroenterology. 2012;142: S46-S47.
33. Beatty JK, Akierman SV, Rioux KP, et al. Gut microbiota biofilm disruptions by Giardia: pathology in human enterocytes and germ-free mice. FASEB J. 2013;27:131.
34. Beatty JK, Bhargava A, Motta JP, et al. Giardia duodenalis cysteine proteases modify human microbiota biofilms: a role in post-infectious epithelial dysfunction?. Can J Gastroenterol Hepat. 2014;28:16.
35. Goubern M, Andriamihaja M, Nubel T, et al. Sulfide, the first inorganic substrate for human cells. FASEB J. 2007;21:1699-1706.
36. Wallace JL, Ferraz JG, Muscara MN. Hydrogen sulfide: an endogenous mediator of resolution of inflammation and injury. Antioxid Redox Signal. 2012;17:58-67.
37. Fiorucci S, Orlandi S, Mencarelli A, et al. Enhanced activity of a hydrogen sulphid-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. Br J Pharmacol. 2014;150:996-1002.
38. Flannigan KL, Agbor TA, Blackler RW, et al. Impaired hydrogen sulfide synthesis and IL-10 signaling underlie hyperhomocysteinemia-Associated exacerbation of colitis. Proc Natl Acad Sci U S A. 2014;111: 13559-13564.
39. Zayachkivska O, Havryluk O, Hrycevych N, et al. Cytoprotective effects of hydrogen sulfide in novel rat models of non-erosive esophagitis. PLoS One. 2014;9:e110688.
40. Zanardo RC, Brancaleone V, Distrutti E, et al. Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J. 2006;20:2118-2120.
41. Papapetropoulos A, Pyriochou A, Altaany Z, et al. Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc Natl Acad Sci U S A. 2009; 106:21972-21977.
42. Mariggio MA, Minunno V, Riccardi S, et al. Sulfide enhancement of PMN apoptosis. Immunopharmacol Immunotoxicol. 1998;20:399-408.
43. Dufton N, Natividad J, Verdu EV, et al. Hydrogen sulfide and resolution of acute inflammation: a comparative study utilizing a novel fluorescent probe. Sci Rep. 2012;2:499.
44. Palinkas Z, Furtmuller PG, Nagy A, et al. Interactions of hydrogen sulfide with myeloperoxidase. Br J Pharmacol. [published online ahead of print May 13, 2014]. DOI: 10.1111/bph.12769.
45. Roediger WE, Duncan A, Kapaniris O, et al. Sulphide impairment of substrate oxidation in rat colonocytes: a biochemical basis for ulcerative colitis?. Clin Sci (Lond). 1993;85:623-627.
46. Attene-Ramos MS, Wagner ED, Plewa MJ, et al. Evidence that hydrogen sulfide is a genotoxic agent. Mol Cancer Res. 2006;4:9-14.
47. Kimura H, Shibuya N, Kimura Y, et al. Hydrogen sulfide is a signaling molecule and a cytoprotectant. Antioxid Redox Signal. 2012;17:45-57.
48. Elrod JW, Calvert JW, Morrison J, et al. Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci U S A. 2007;104:15560-15565.
49. Mimoun S, Andriamihaja M, Chaumontet C, et al. Detoxification of H2S by differentiated colonic epithelial cells: implication of the sulfide oxidizing unit and of the cell respiratory capacity. Antioxid Redox Signal. 2012; 17:1-10.
50. Flannigan KL, McCoy KD, Wallace JL. Eukaryotic and prokaryotic contributions to colonic hydrogen sulfide synthesis. Am J Physiol Gastrointest Liver Physiol. 2011;301:G188-G193.
51. Shen X, Carlstrom M, Borniquel S, et al. Microbial regulation of host hydrogen sulfide bioavailability and metabolism. Free Radic Biol Med. 2013;60:195-200.
52. Kimura Y, Mikami Y, Osumi K, et al. Polysulfides are possible H2S-derived signalling molecules in the rat brain. FASEB J. 2013;27:2451-2457.
53. Blackler RW, Motta JP, Manko A, et al. Hydrogen sulfide protects against NSAID-enteropathy through modulation of bile and the microbiota. Br J Pharmacol. 2014;172:992-1004.
54. Johansson ME, Gustafsson JK, Holmen-Larsson J, et al. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut. 2014;63:281-291.
55. Wlodarska M, Willing B, Keeney KM, et al. Antibiotic treatment alters the colonic mucus layer and predisposes the host to exacerbated Citrobacter rodentium-induced colitis. Infect Immun. 2011;79:1536-1545.